Adverum Biotechnologies Inc
ADVM4.320USD
+0.030+0.70%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
90.64MMarket Cap
LossP/E TTM
More Details of Adverum Biotechnologies Inc Company
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Adverum Biotechnologies Inc Info
Ticker SymbolADVM
Company nameAdverum Biotechnologies Inc
IPO dateJul 31, 2014
CEODr. Laurent Fischer, M.D.
Number of employees155
Security typeOrdinary Share
Fiscal year-endJul 31
Address100 Cardinal Way
CityREDWOOD CITY
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94063
Phone16506491004
Websitehttps://adverum.com/
Ticker SymbolADVM
IPO dateJul 31, 2014
CEODr. Laurent Fischer, M.D.
Company Executives of Adverum Biotechnologies Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Chief Development Officer
Chief Development Officer
52.75K
-1.72%
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.82K
--
Dr. Laurent Fischer, M.D.
Dr. Laurent Fischer, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Szilard Kiss, M.D.
Dr. Szilard Kiss, M.D.
Director
Director
--
--
Dr. Rabia Gurses Ozden, M.D.
Dr. Rabia Gurses Ozden, M.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Reed V. Tuckson ,M.D.
Dr. Reed V. Tuckson ,M.D.
Independent Director
Independent Director
--
--
Ms. Linda M. Rubinstein
Ms. Linda M. Rubinstein
Chief Financial Officer
Chief Financial Officer
--
--
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Dr. C. David Nicholson, Ph.D.
Dr. C. David Nicholson, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jason L. Mitchell
Mr. Jason L. Mitchell
Chief Commercial Officer
Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Chief Development Officer
Chief Development Officer
52.75K
-1.72%
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.82K
--
Dr. Laurent Fischer, M.D.
Dr. Laurent Fischer, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Szilard Kiss, M.D.
Dr. Szilard Kiss, M.D.
Director
Director
--
--
Dr. Rabia Gurses Ozden, M.D.
Dr. Rabia Gurses Ozden, M.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Reed V. Tuckson ,M.D.
Dr. Reed V. Tuckson ,M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BML Capital Management LLC
13.90%
Principia Wealth Advisory, LLC
9.22%
TCG Crossover Management, LLC
8.17%
Frazier Life Sciences Management, L.P.
5.13%
Stern (Augustus)
5.08%
Other
58.50%
Shareholders
Shareholders
Proportion
BML Capital Management LLC
13.90%
Principia Wealth Advisory, LLC
9.22%
TCG Crossover Management, LLC
8.17%
Frazier Life Sciences Management, L.P.
5.13%
Stern (Augustus)
5.08%
Other
58.50%
Shareholder Types
Shareholders
Proportion
Investment Advisor
39.57%
Individual Investor
11.58%
Private Equity
6.76%
Hedge Fund
6.58%
Venture Capital
4.90%
Investment Advisor/Hedge Fund
3.65%
Research Firm
2.83%
Corporation
0.82%
Other
23.30%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
181
14.14M
64.27%
-7.96M
2025Q2
193
17.24M
82.54%
-5.34M
2025Q1
200
18.99M
90.93%
-3.09M
2024Q4
197
18.17M
87.35%
-2.16M
2024Q3
205
18.40M
88.51%
-3.17M
2024Q2
198
18.25M
87.99%
-2.40M
2024Q1
209
17.03M
82.27%
+429.10K
2023Q4
203
6.60M
65.29%
-2.40M
2023Q3
243
6.95M
68.86%
-2.49M
2023Q2
271
6.98M
69.47%
-2.29M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BML Capital Management LLC
3.06M
14.57%
--
--
Jun 30, 2025
Principia Wealth Advisory, LLC
2.03M
9.67%
+332.30K
+19.58%
Jun 30, 2025
TCG Crossover Management, LLC
1.80M
8.56%
--
--
Jun 30, 2025
Frazier Life Sciences Management, L.P.
1.13M
5.38%
+59.81K
+5.59%
Aug 12, 2025
Stern (Augustus)
1.12M
5.32%
+1.12M
--
Oct 29, 2024
Rush (Ryan Bradford)
1.05M
5%
+1.05M
--
Dec 17, 2024
The Vanguard Group, Inc.
883.94K
4.21%
-145.39K
-14.12%
Jun 30, 2025
Renaissance Technologies LLC
570.67K
2.72%
+411.10K
+257.63%
Jun 30, 2025
5AM Ventures
541.67K
2.58%
--
--
Jun 30, 2025
Versant Ventures
506.82K
2.42%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
iShares Micro-Cap ETF
0.02%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Global X Russell 2000 ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
Dimensional US Core Equity 1 ETF
0%
Proshares Ultra Russell 2000
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 18, 2024
Merger
10→1
Mar 18, 2024
Merger
10→1
Mar 18, 2024
Merger
10→1
Mar 18, 2024
Merger
10→1
Date
Type
Ratio
Mar 18, 2024
Merger
10→1
Mar 18, 2024
Merger
10→1
Mar 18, 2024
Merger
10→1
Mar 18, 2024
Merger
10→1
